WYNZORA Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Wynzora patents expire, and when can generic versions of Wynzora launch?
Wynzora is a drug marketed by MC2 and is included in one NDA. There is one patent protecting this drug.
This drug has nineteen patent family members in fourteen countries.
The generic ingredient in WYNZORA is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.
DrugPatentWatch® Generic Entry Outlook for Wynzora
Indicators of Generic Entry
Summary for WYNZORA
International Patents: | 19 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in WYNZORA? | WYNZORA excipients list |
DailyMed Link: | WYNZORA at DailyMed |

Pharmacology for WYNZORA
Drug Class | Corticosteroid Vitamin D Analog |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for WYNZORA
US Patents and Regulatory Information for WYNZORA
WYNZORA is protected by one US patents and one FDA Regulatory Exclusivity.
Patents protecting WYNZORA
Topical composition
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
FDA Regulatory Exclusivity protecting WYNZORA
NEW DOSAGE FORM
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mc2 | WYNZORA | betamethasone dipropionate; calcipotriene | CREAM;TOPICAL | 213422-001 | Jul 20, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Mc2 | WYNZORA | betamethasone dipropionate; calcipotriene | CREAM;TOPICAL | 213422-001 | Jul 20, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for WYNZORA
See the table below for patents covering WYNZORA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Austria | 516797 | See Plans and Pricing | |
Japan | 2010521445 | See Plans and Pricing | |
South Africa | 200906382 | POLYAPHRON TOPICAL COMPOSITION WITH VITAMIN D AND CORTICOTEROID | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |